Significance of Matrix Metalloproteinase 9 Expression as Supporting Marker to Cytokeratin 19 mRNA in Sentinel Lymph Nodes in Breast Cancer Patients.
One-step nucleic acid amplification (OSNA) detects and quantifies, with the use of a polymerase chain reaction, the presence of cytokeratin 19 mRNA in sentinel lymph nodes. The main advantage of the OSNA assay is the avoidance of second surgery in case of positive sentinel lymph node diagnosis. The objective of this study was to evaluate the significance of matrix metalloproteinase 9 expression by immunohistochemistry as supporting marker to cytokeratin 19 mRNA in sentinel lymph nodes in breast cancer patients and to relate this expression with clinicopathological data. This study was conducted on fresh sentinel lymph nodes obtained from 40 patients with tumors classified as carcinoma of no special type. The presence of metastatic cells in the slices of lymph nodes was evaluated by immunohistochemistry using antibodies for CK19 and MMP-9. Expression of CK19 and MMP-9 in lymph nodes was also confirmed by means of Western blot analysis. Results indicated that the strongest correlation with CK19 mRNA was displayed by MMP-9, CK19 (by immunohistochemistry, IHC), and nodal metastases (p < 0.001). Higher histological grading also positively correlated with CK19 mRNA, however that correlation was less significant. Since MMP-9 shows very strong correlation with CK19 mRNA in breast carcinoma of no special type metastases, expression of MMP-9 in sentinel lymph nodes should be considered as useful method whenever OSNA analysis is not available.
Department of Gynecology and Obstetrics, Wrocław Medical University, Chałubińskiego 3, 50-368 Wrocław, Poland. marcopolo2135@gmail.com.
Marek
M
Murawski
Department of Pathology, Wrocław Medical University, Marcinkowskiego 1, 50-368 Wrocław, Poland. marta1wozniak@wp.pl.
Marta
M
Woźniak
Department of Pathology, Wrocław Medical University, Marcinkowskiego 1, 50-368 Wrocław, Poland. kamila.dus@gmail.com.
Kamila
K
Duś-Szachniewicz
Division of Pathology, Sokołowski Hospital Wałbrzych, Sokołowskiego 4, 58-309 Wałbrzych, Poland. hp2010@wp.pl.
Paweł
P
Kołodziej
Department of Pathology, Wrocław Medical University, Marcinkowskiego 1, 50-368 Wrocław, Poland. rzemarta@wp.pl.
Marta
M
Rzeszutko
Department of Pathology, Wrocław Medical University, Marcinkowskiego 1, 50-368 Wrocław, Poland. ziolkows@interia.pl.|Division of Pathology, Sokołowski Hospital Wałbrzych, Sokołowskiego 4, 58-309 Wałbrzych, Poland. ziolkows@interia.pl.
Piotr
P
Ziółkowski
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D002277:Carcinoma / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053539:Keratin-19 / Q000235:genetics / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000378:metabolism; D000071036:Sentinel Lymph Node / Q000378:metabolism*
D014408:Biomarkers, Tumor; D053539:Keratin-19; D012333:RNA, Messenger; C579270:MMP9 protein, human; D020780:Matrix Metalloproteinase 9
cytokeratin 19; invasive breast carcinoma of no special type; matrix metalloproteinase 9; one-step nucleic acid amplification